- Home
- PULM vs ICU Comparison
PULM vs ICU Comparison
Compare PULM & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PULM | ICU |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 9.1M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | PULM | ICU |
|---|---|---|
| Price | $2.06 | $2.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.2K | ★ 53.7K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,910,000.00 | N/A |
| Revenue This Year | N/A | $1,043.70 |
| Revenue Next Year | N/A | $54.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5069.93 | N/A |
| 52 Week Low | $1.63 | $0.22 |
| 52 Week High | $9.37 | $2.98 |
Technical Indicators
Market Signals| Indicator | PULM | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 37.45 | 55.54 |
| Support Level | N/A | $2.26 |
| Resistance Level | $5.05 | $2.73 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 22.60 | 41.32 |
Price Performance
Historical ComparisonAbout PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.